Abstract Number: 0773 • ACR Convergence 2024
Anti-Citrullinated Histone Antibody CIT-013 Targets NETs in Inflamed Joints and Halts NET-mediated Joint Deterioration
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of many immune-mediated inflammatory diseases (IMIDs). Though NETosis-targeting therapeutics have shown potential as effective treatments, currently…Abstract Number: 0845 • ACR Convergence 2024
Weight Loss, Disease Activity, and Patient Reported Outcomes in Patients with Musculoskeletal and Autoimmune Diseases Taking Weight Loss Therapies
Background/Purpose: With the popularity of medication-assisted weight loss, the current study seeks to characterize the association of weight loss, disease activity, and patient reported outcomes…Abstract Number: 0939 • ACR Convergence 2024
A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease of synovial joints, and it affects over 1 per cent of the population worldwide. Uncontrolled or…Abstract Number: 1105 • ACR Convergence 2024
PDGFA and TGFB1, Key Genes to Discriminate Autoimmune Diseases-Related Interstitial Lung Disease from Idiopathic Pulmonary Fibrosis?
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the main causes of mortality in patients with autoimmune diseases (ADs) [1]. The early diagnosis of AD-ILD+…Abstract Number: 1295 • ACR Convergence 2024
A Qualitative Survey of Internal Medicine Residents’ Understanding of Appropriate ANA Testing: An 11-Year Update Since the ‘Choosing Wisely’ Campaign
Background/Purpose: ANA testing is recommended when there is a reasonable clinical suspicion for systemic autoimmune disease. Testing in the setting of low pre-test probability, however,…Abstract Number: 1531 • ACR Convergence 2024
Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Background/Purpose: Autoimmune disease patients treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), or B cell-depleting therapies (BCDT) exhibit reduced humoral responses following primary two-dose COVID-19…Abstract Number: 1652 • ACR Convergence 2024
Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome
Background/Purpose: Extracellular Vesicles (EVs) are double lipid bilayer-enclosed membranous vesicles, produced and discharged from almost all cells. EVs are known for inter-cellular communication by releasing…Abstract Number: 1784 • ACR Convergence 2024
T-bet Expressing B Cells as a Putative Prognostic and Therapeutic Biomarker for Human SLE
Background/Purpose: T-bet+ B cells, known as age-associated B cells (ABCs) and/or double-negative B cells (DN), expand in various autoimmune diseases. This study aimed to clarify…Abstract Number: 1857 • ACR Convergence 2024
Thymic Mimetic Cells in Humans, Mice and Fish Are Evolutionarily Ancient with Species-specific Adaptations
Background/Purpose: Thymic mimetic cells are molecular hybrids between medullary thymic epithelial cells (mTECs) and diverse peripheral cell types. They are involved in eliminating autoreactive T…Abstract Number: 1982 • ACR Convergence 2024
Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) such as rheumatoid arthritis and systemic lupus erythematosus affect 3-5% of Americans and causes significant morbidity due to chronic…Abstract Number: 2171 • ACR Convergence 2024
A Qualitative Exploration of Oral Healthcare Needs Amongst Canadian Patients with Rheumatic Diseases and Their Providers
Background/Purpose: Patients with autoimmune rheumatic diseases (RDs) have a high prevalence of oral manifestations and/or oral side effects from immunomodulatory medications. These factors combined with…Abstract Number: 2411 • ACR Convergence 2024
Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study
Background/Purpose: LN is prevalent in SLE, occurring in up to 50% of patients. Treatment response is evaluated by improvement in proteinuria and renal function, and…Abstract Number: 2549 • ACR Convergence 2024
VISTA Deficiency Alters the Skin Immune Cell Composition and Confers Skin Sensitivity to UV Light
Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of cutaneous lupus erythematosus (CLE) that is exacerbated by ultraviolet (UV) light.…Abstract Number: 2681 • ACR Convergence 2024
Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021
Background/Purpose: Careful assessment of individuals’ social determinants of health (SDOH) that affect systemic lupus erythematosus (SLE) is crucial, as such evidence will improve care and…Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 80
- Next Page »